Literature DB >> 22224728

The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma.

Zdravko Mitrovic, Martin Bast, Philip J Bierman, Robert G Bociek, Julie M Vose, Wing C Chan, James O Armitage.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22224728     DOI： 10.1111/j.1365-2141.2011.08998.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center.

Authors:  Agustin Avilés; M Jesús Nambo; Natividad Neri
Journal:  Med Oncol       Date:  2013-03-01       Impact factor: 3.064

2.  Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.

Authors:  Matthew R Wilson; Toby A Eyre; Nicolas Martinez-Calle; Matthew Ahearne; Katrina E Parsons; Gavin Preston; Jahanzaib Khwaja; Jeremy Schofield; Johnathon Elliot; Almurtadha Mula Kh; Nimish Shah; Cheuk-Kie Cheung; Matthew A Timmins; Thomas Creasey; Kim Linton; Jeffery Smith; Christopher P Fox; Fiona Miall; Kate Cwynarski; Pamela McKay
Journal:  Blood Adv       Date:  2020-08-11

3.  Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).

Authors:  Francisco-Javier Peñalver; Juan-Manuel Sancho; Adolfo de la Fuente; María-Teresa Olave; Alejandro Martín; Carlos Panizo; Elena Pérez; Antonio Salar; Alberto Orfao
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

Review 4.  Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Authors:  Chan Yoon Cheah; John F Seymour
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

5.  Central nervous system involvement in AIDS-related lymphomas.

Authors:  Stefan K Barta; Jitesh Joshi; Nicolas Mounier; Xiaonan Xue; Dan Wang; Josep-Maria Ribera; Jose-Tomas Navarro; Christian Hoffmann; Kieron Dunleavy; Richard F Little; Wyndham H Wilson; Michele Spina; Lionel Galicier; Ariela Noy; Joseph A Sparano
Journal:  Br J Haematol       Date:  2016-04-07       Impact factor: 6.998

6.  Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.

Authors:  Toby A Eyre; Faouzi Djebbari; Amy A Kirkwood; Graham P Collins
Journal:  Haematologica       Date:  2019-09-05       Impact factor: 9.941

Review 7.  Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.

Authors:  David Qualls; Jeremy S Abramson
Journal:  Haematologica       Date:  2018-12-20       Impact factor: 9.941

8.  A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.

Authors:  C Y Cheah; K E Herbert; K O'Rourke; G A Kennedy; A George; P L Fedele; M Gilbertson; S Y Tan; D S Ritchie; S S Opat; H M Prince; M Dickinson; K Burbury; M Wolf; E H Januszewicz; C S Tam; D A Westerman; D A Carney; S J Harrison; J F Seymour
Journal:  Br J Cancer       Date:  2014-07-29       Impact factor: 7.640

9.  Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.

Authors:  M Gleeson; N Counsell; D Cunningham; N Chadwick; A Lawrie; E A Hawkes; A McMillan; K M Ardeshna; A Jack; P Smith; P Mouncey; C Pocock; J A Radford; J Davies; D Turner; A Kruger; P Johnson; J Gambell; D Linch
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.